Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
Pred 726 dňami
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
Pred 981 dňami
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
Pred 1008 dňami
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
Pred 1080 dňami
FTSE 100 Flat In Lackluster Trade; Bank Stocks Drifting Lower
U.K. stocks are somewhat subdued in lackluster trade on Wednesday as investors remain a bit reluctant to make significant moves due to a lack of triggers.
The benchmark FTSE 100 was at 9,266.25 a little before noon, up 0.45 points over previous close.
RTTNews
|
Pred 27 minútami
CAC 40 Advances After Recent Losses
Despite the uncertainty on the political front, the French market is up in positive territory on Wednesday due largely to some bargain hunting at several counters after two successive days of declines. Investors are also looking ahead to AI giant Nvidia's earnings updates.
RTTNews
|
Pred 42 minútami
DAX Remains Weak Despite Paring Some Early Losses
German stocks are down in negative territory in cautious trade on Wednesday amid political uncertainty in France ahead of a confidence vote early next month, and anxiety ahead of Nvidia's earnings for clues on the AI trade.
RTTNews
|
Pred 59 minútami
Mixed Sentiment In Asian Markets
Asian markets moved in a mixed fashion on Wednesday amidst anxiety ahead of release of earnings update by chip-giant NVIDIA.
RTTNews
|
Pred 1 h 9 min
